Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective

Von Dach, Elodie; Morel, C M; Murthy, A; Pagani, L; Macedo-Vinas, M; Olearo, Flaminia; Harbarth, Stéphan Juergen

doi:10.1016/j.cmi.2017.02.011

Scientific article

Open access

English

Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective

ContributorsVon Dach, Elodie; Morel, C M; Murthy, A; Pagani, L; Macedo-Vinas, M; Olearo, Flaminia; Harbarth, Stéphan Juergen

Published inClinical Microbiology and Infection, vol. 23, no. 9, p. 659-666

Publication date2017

Abstract

Few industry-independent studies have been conducted to compare the relative costs and benefits of drugs to treat methicillin-resistant Staphylococcus aureus (MRSA) infection. We performed a stochastic cost-effectiveness analysis comparing two treatment strategies-linezolid versus trimethoprim-sulfamethoxazole plus rifampicin-for the treatment of MRSA infection.

Affiliation

Faculté de médecine / Section de médecine clinique / Département de médecine

Research group

Epidémiologie et contrôle de la résistance aux antibiotiques (866)

Citation (ISO format)

VON DACH, Elodie et al. Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective. In: Clinical Microbiology and Infection, 2017, vol. 23, n° 9, p. 659–666. doi: 10.1016/j.cmi.2017.02.011

Article (Published version)

CC BY-NC-ND

Identifiers

PID : unige:99033
DOI : 10.1016/j.cmi.2017.02.011
PMID : 28232163

ISSN of the journal1198-743X

443views

236downloads

Creation10/20/2017 7:25:00 PM

First validation10/20/2017 7:25:00 PM

Update time03/15/2023 2:20:53 AM

Status update03/15/2023 2:20:52 AM

Last indexation09/25/2023 7:53:00 AM

Archive ouverte UNIGE

Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective

Technical informations